Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

67.30 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
66 67 Next >
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a 
Via MarketBeat
Exposures Product Safety
Could This Vaccine Become Sanofi's Latest Blockbuster?
This vaccine candidate could be approved in newborns and infants later this year. 
Via The Motley Fool
Could This Be Novartis' Next Blockbuster Medicine?
The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug. 
Via The Motley Fool
7 Dividend Stocks to Buy for a Stable Income Stream
These are the dividend stocks to buy for a regular income stream and potential capital gains as these stocks trade at attractive valuations. 
Via InvestorPlace
Mergers and Acquisitions in 2023 Off To A Strong Start
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road. 
Via MarketBeat
Exposures Product Safety
AZN Stock Under Pressure
Shares in UK-headquartered AstraZeneca are back under heavy selling pressure on Monday as the stock extends recent losses. 
Via Talk Markets
The Top Healthcare Stocks to Buy With $100
Don't overlook these big-name foreign healthcare stocks. 
Via The Motley Fool
Is Johnson & Johnson Still a Good Dividend Stock to Buy?
A disappointing fourth-quarter performance has some investors worried about the giant healthcare conglomerate's outlook. 
Via The Motley Fool
AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.
From AstraZeneca
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paya Holdings Inc. (Nasdaq – PAYA), CinCor Pharma, Inc. (Nasdaq – CINC), Albireo (Nasdaq – ALBO), Duck Creek Technologies (Nasdaq - DCT)
From Brodsky & Smith LLC
Via GlobeNewswire
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
After years of lab failures, the companies could crack open a multibillion-dollar market. 
Via Investor's Business Daily
AstraZeneca’s Next “Wonder Drug”
Enhertu is an antibody-drug conjugate, a type of therapy designed to do minimal damage to healthy, non-cancerous cells. Wall Street analysts believe that Enhertu has the potential to become a key... 
Via Talk Markets
Initiatives For Development of Gamma Delta T Cell Therapies Driven by Large Number of Clinical Trials
EQNX::TICKER_START (NASDAQ:TCBP),(NASDAQ:CRDF),(NASDAQ:CYAD),(NASDAQ:RIGL),(NASDAQ:AZN) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19 Product Safety
AbbVie Stock: Dividend King ABBV Overview
Via MarketBeat
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
From HUTCHMED (China) Limited
Via GlobeNewswire
Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
Johnson & Johnson stock has been struggling to break out of a correction. It formed a cup-shaped pattern that appeared to add a handle but broke down last week. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices
Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch... 
Via Talk Markets
The Viral “Tripledemic” Opportunity
Between Covid, the flu, and RSV, investors in over-the-counter consumer pharmaceutical companies might be wondering if now is a logical time to up their holdings in the companies that make cold and flu... 
Via Talk Markets
3 Growth Stocks Poised for Huge Gains in 2023
These big pharmaceuticals are poised for back-to-back big years. 
Via The Motley Fool
Why These Two Biotech Stocks Blasted Higher This Week
There's nothing like a big-premium buyout to send a company's share price to the moon. 
Via The Motley Fool
Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review
Sharp Tesla price cuts and some notable earnings were in focus. 
Via Investor's Business Daily
Could This New Drug Launch Be a Hit for Viatris?
Viatris and Kindeva Drug Delivery could soon launch a generic version of AstraZeneca's Symbicort. 
Via The Motley Fool
AstraZeneca's New Asthma Treatment for Adults Gets Green Light from FDA
Via Benzinga
AIRSUPRA™ (PT027) approved in the US for asthma
From AstraZeneca
Via Business Wire
AstraZeneca Stock Nabs Breakout After $1.8 Billion CinCor Buyout
CinCor will bolster AstraZeneca's growing cardio-renal business. 
Via Investor's Business Daily
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Paya Holdings Inc. (Nasdaq – PAYA), CinCor Pharma, Inc. (Nasdaq – CINC), Albireo (Nasdaq – ALBO), Duck Creek Technologies (Nasdaq - DCT)
From Brodsky & Smith LLC
Via GlobeNewswire
CinCor Pharma (NASDAQ: CINC) Enters Into Agreement to be Acquired by AstraZeneca (NASDAQ: AZN) for $1.3 Billion
CinCor Pharma, Inc. (NASDAQ: CINC) is a clinical-stage biopharmaceutical company, which is focused on the research and development of treatments 
Via Spotlight Growth
AstraZeneca To Acquire Blood-Pressure Drugmaker In $1.8 Billion Deal
AstraZeneca stock wavered as it agreed to buy CinCor Pharma, maker of blood pressure drug baxdrostat for $1.8 billion. CINC stock soared. 
Via Investor's Business Daily
Why Is CinCor (CINC) Stock Up 138% Today?
CinCor (CINC) stock is rocketing higher on Monday following news that AstraZeneca (AZN) is acquiring the company for up to $1.8 billion. 
Via InvestorPlace
Tesla's Delivery Wait Times Go Up, China Wants To Secure License For Generic Version Of Pfizer's Paxlovid, India-Made iPhone Exports Surpass $2.5B: Today's Top Stories
Bloomberg 
Via Benzinga
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
66 67 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.